Replies to post #2640 on Skye Bioscience Inc (SKYE)

[cjarmstrong]

I've read that Cesamet claimed to have ~90% market share in Canada as well.

I'm sure it's more than $50mm, but the market for a suppository formulation wouldn't be as large, and if they in-license the royalty will be low.